Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 15, 2016, regarding events occurring on June 9, 2016. The filing addresses a change in the Company's principal financial officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
The Board of Directors appointed David-Alexandre C. Gros, M.D., as the Company's Principal Financial Officer, effective July 1, 2016. Dr. Gros succeeds Michael P. Mason in this role. Dr. Gros will oversee finance, business development, corporate communications, and investor relations. Mr. Mason will continue as Vice President, Finance, Treasurer, and Principal Accounting Officer.
Guidance, Outlook, and Risks
The filing states that the reported changes did not result in any change in compensation for Dr. Gros or Mr. Mason. No financial guidance, outlook, or new risk factors were disclosed in this document.
Investor Verification Points
- Confirm the effective date of Dr. Gros's new role as Principal Financial Officer (July 1, 2016).
- Review the Company's Proxy Statement for the year ended December 31, 2015, for details on Dr. Gros's compensation.
- Verify the continued role of Michael P. Mason as Principal Accounting Officer.